ImmuCell (NASDAQ:ICCC) Share Price Crosses Above 200 Day Moving Average – What’s Next?

ImmuCell Corporation (NASDAQ:ICCC) shares crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $8.64 and traded as high as $10.49. ImmuCell shares last traded at $10.06, with a volume of 11,130 shares trading hands.

Analysts Set New Price Targets

ICCC has been the topic of several research analyst reports. Wall Street Zen raised ImmuCell to a “strong-buy” rating in a report on Saturday, June 27th. Weiss Ratings raised ImmuCell from a “sell (d-)” rating to a “hold (c-)” rating in a report on Tuesday. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, ImmuCell currently has an average rating of “Hold”.

ImmuCell Stock Performance

The business’s fifty day moving average is $10.53 and its 200-day moving average is $8.64. The company has a quick ratio of 2.71, a current ratio of 4.75 and a debt-to-equity ratio of 0.22. The company has a market cap of $91.36 million, a PE ratio of 125.77 and a beta of 0.54.

ImmuCell (NASDAQ:ICCC) last announced its earnings results on Thursday, August 13th. The biotechnology company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of $0.05 by $0.15. The business had revenue of $7.19 million during the quarter, compared to analysts’ expectations of $5.40 million. ImmuCell had a net margin of 2.57% and a return on equity of 2.69%.

Insider Activity at ImmuCell

In related news, CEO Boekhorst Paul Francis Oliv Te acquired 8,000 shares of ImmuCell stock in a transaction dated Thursday, June 18th. The stock was purchased at an average cost of $9.49 per share, for a total transaction of $75,920.00. Following the purchase, the chief executive officer directly owned 17,785 shares of the company’s stock, valued at approximately $168,779.65. This trade represents a 81.76% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 5.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On ImmuCell

Institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC grew its holdings in ImmuCell by 4.2% during the second quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company’s stock valued at $500,000 after purchasing an additional 2,907 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of ImmuCell by 3.2% in the first quarter. Dimensional Fund Advisors LP now owns 56,030 shares of the biotechnology company’s stock worth $355,000 after buying an additional 1,749 shares during the period. Mesirow Financial Investment Management Inc. raised its stake in shares of ImmuCell by 199.6% in the fourth quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company’s stock worth $224,000 after buying an additional 24,303 shares during the period. Finally, Militia Capital Management LLC purchased a new position in shares of ImmuCell during the 1st quarter valued at about $114,000. 13.47% of the stock is currently owned by hedge funds and other institutional investors.

About ImmuCell

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.